about
Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.Epigenomic evolution in diffuse large B-cell lymphomasDose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana LinfomiLenalidomide in diffuse large B-cell lymphomas.Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.XVI. CNS prophylaxis in aggressive lymphomas: for whom and how.A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphomaAntiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma.Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyPrognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation.Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial.Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.The risk of CNS involvement in aggressive lymphomas in the rituximab era.Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.Highlights in lymphoma: overview of the 11th International Conference on Malignant Lymphoma.Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione ItaliaRadiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?Integrated profiling of diffuse large B-cell lymphoma with 7q gain.Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab.Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
P50
Q30235296-5CC5D80D-73F9-42AC-AD4A-88F393755576Q33408772-8EEF1FED-73ED-420B-8FD1-E53ED72548C5Q33415354-E345E00B-3B7D-4EA0-AF6B-3FA43D2BD0B7Q33431457-1F2518AA-1E39-4E20-9151-37E7E7EA2075Q33437445-A51A0AF8-FB43-4F0B-9EC9-B2C3CC164C92Q34454573-FA495D6C-66AA-4172-A2B6-1D1C811E0CF0Q35543203-CF3CC702-4D0F-45AC-A751-3A50F3FED1E0Q37334956-B3EA513A-1B9B-4962-87F1-0F3437671B6BQ37618904-400E64CA-B3B8-48FF-99E7-935677F3862DQ38026039-E45066E8-F496-428F-AC6B-F2D0CD86F795Q38047385-84EABC9A-32D2-46C6-B434-7C7661D9CAFDQ38115237-BA53DC71-1A99-41BB-B100-EEFDE8356A2BQ38364912-E61BB22D-ED36-47C0-A2AA-B7FEE5A1BFA2Q38408414-A4FABBBF-4C7B-4023-814F-E0764ED365C6Q38878814-1496205D-CE33-4FA7-86F3-20BA2DD2E140Q39007009-8F90E580-3826-41BF-BF0B-F51A8CCD7B2DQ39020632-65E9F394-43E1-49CC-AACD-9DE605246816Q40138440-BB1BC010-C075-4A3B-BFF4-2D09BB07DE67Q40775154-BE94C3E2-72A4-4FFF-8645-FC4A764100DFQ42919408-471939CC-22E1-400B-90A0-69167D8DB8C8Q43223088-36969051-94AF-41B9-8243-33CEBDAAE429Q43254582-244BD5F8-3CA2-44BF-AE87-3A3901B8F9D1Q43571496-3D3E15F2-9442-4BD0-99C7-1508504A6B34Q43703690-53DCA556-E8D0-40CA-8E4F-E388372A4ABFQ44483495-C96EFAC2-A2B1-489C-9233-4FA49C04E722Q45018813-16361434-44A4-405F-973F-D39788162BE7Q45711675-ACF2A12F-D202-4FAE-AEE6-1F70EE2B86C2Q45993077-18E61F0B-FB80-441E-85CE-4E9DD0E081B8Q46008254-EFC1EBE0-355C-4A08-8E45-1BE525373E3FQ46102733-E5C6402F-0ED4-4054-808C-E7D5B0719D68Q46563541-A623B232-AEBC-4595-8CBE-6144E83ECDF1Q46642659-DF90A032-C813-446B-913A-DDFC4CD1599EQ47741058-896759DB-3EBB-4881-8781-35E6C2ECE7B9Q47857984-0E07A585-6BC1-4BF0-9532-BF55BB168D18Q48359090-6811F58D-73C7-499E-B94F-EE61B6960984Q49588788-DA022564-B2E5-4BED-AC62-CFF40B3A76D8Q51438121-F9B393B2-ED30-426B-9D5A-8BFA60A130A5Q51490388-7D0F10CB-FCC2-4A4F-A007-C6AAABC39772Q51677133-9D29431E-9C2E-40F7-A6CD-2E1E67AA0C0BQ52317892-7CB32EAA-1872-4A08-97E3-058967A12812
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Annalisa Chiappella
@ast
Annalisa Chiappella
@en
Annalisa Chiappella
@es
Annalisa Chiappella
@nl
Annalisa Chiappella
@sl
type
label
Annalisa Chiappella
@ast
Annalisa Chiappella
@en
Annalisa Chiappella
@es
Annalisa Chiappella
@nl
Annalisa Chiappella
@sl
prefLabel
Annalisa Chiappella
@ast
Annalisa Chiappella
@en
Annalisa Chiappella
@es
Annalisa Chiappella
@nl
Annalisa Chiappella
@sl
P106
P1153
23970064300
P21
P31
P496
0000-0002-2977-0098